The Cys-dependent strategy of NRF2 activation adopted by MSL TNBC cells is all the more interesting as breast cancer is one of the cancers with the lowest number of mutations or copy number variations (CNV) in the KEAP1, CUL3 or NFE2L2 genes that would lead to constitutive activation of this pathway and are more common in other cancers (Fig. 3H, I) [22]. The gene discussed is NFE2L2; the disease is breast cancer.